FDA links Actos^® with a heightened risk of bladder cancer

You may be eligible for a
CASH PAYMENT

Millions of Americans have been prescribed products containing the generic form of Actos^®.

In June of this year the U.S. Food & Drug Administration (FDA) issued a warning^[1] about the popular diabetes drug Actos^® (pioglitazone). The FDA had found that the use of pioglitazone for more than a year may be linked to an increased risk of bladder cancer.

France and Germany move to restrict use

The FDA warning was based on a study that shows that an increased risk of bladder cancer was found among patients with the longest exposure to pioglitazone, and in those exposed to the highest cumulative dose of pioglitazone. The warning notes that France and Germany both moved to restrict the use of pioglitazone after a French study linked an increased risk of bladder cancer to long-term use.

Actos is widely prescribed for diabetes control

Pioglitazone is also a key ingredient in the drugs Actoplus Met, Actoplus Met XR and Duetact. In the first ten months of 2010, more than 2.3 million patients were prescribed a pioglitazone-containing product.

Protect your rights.
Get compensated for your injuries.

If you or a loved one developed bladder cancer or died after using Actos^®, you may be entitled to compensation! Complete our quick intake form to receive a FREE, no-obligation case evaluation.

[1] "FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer", U.S. Food and Drug Administration, June 15, 2010.

File an Actos^® Claim

Complete the form below or call our legal intake center at
(800) 820-4340
to receive your FREE case evaluation: